Kymera Therapeutics Inc (KYMR) - Total Assets
Based on the latest financial reports, Kymera Therapeutics Inc (KYMR) holds total assets worth $1.10 Billion USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See KYMR net assets for net asset value and shareholders' equity analysis.
Kymera Therapeutics Inc - Total Assets Trend (2018–2024)
This chart illustrates how Kymera Therapeutics Inc's total assets have evolved over time, based on quarterly financial data.
Kymera Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Kymera Therapeutics Inc's total assets of $1.10 Billion consist of 52.2% current assets and 47.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 12.3% |
| Accounts Receivable | $947.00K | 0.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Kymera Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see KYMR stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Kymera Therapeutics Inc's current assets represent 52.2% of total assets in 2024, a decrease from 94.5% in 2018.
- Cash Position: Cash and equivalents constituted 12.3% of total assets in 2024, down from 93.3% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 0.1% of total assets.
Kymera Therapeutics Inc Competitors by Total Assets
Key competitors of Kymera Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
Kymera Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.38 | 8.55 | 2.73 |
| Quick Ratio | 7.38 | 8.57 | 4.20 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $456.72 Million | $502.18 Million | $191.72 Million |
Kymera Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Kymera Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.72 |
| Latest Market Cap to Assets Ratio | 6.46 |
| Asset Growth Rate (YoY) | 69.9% |
| Total Assets | $978.03 Million |
| Market Capitalization | $6.32 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Kymera Therapeutics Inc's assets at a significant premium (6.46x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Kymera Therapeutics Inc's assets grew by 69.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Kymera Therapeutics Inc (2018–2024)
The table below shows the annual total assets of Kymera Therapeutics Inc from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $978.03 Million | +69.87% |
| 2023-12-31 | $575.76 Million | -4.54% |
| 2022-12-31 | $603.13 Million | -0.46% |
| 2021-12-31 | $605.90 Million | +24.37% |
| 2020-12-31 | $487.18 Million | +317.45% |
| 2019-12-31 | $116.70 Million | +163.85% |
| 2018-12-31 | $44.23 Million | -- |
About Kymera Therapeutics Inc
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidrad… Read more